Highest-materiality recent filing
BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M
Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.
BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M
Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M
Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M
Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M
Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%
Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance
Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025
Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
BioLife Solutions sells SciSafe for $73M cash; closes Nov 12, 2024
Sold all SciSafe shares to Subzero Purchaser Corp. for $73M; repaid $0.9M of SciSafe debt and paid $3.3M to waive earn-out rights.
BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M
Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M
Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M
Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance
Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).
BioLife Solutions sells Global Cooling for $1, incurs ~$7.4M cash outflows
Sold Global Cooling for $1.00; provided $4.9M to meet $7M cash closing condition.
BioLife Solutions divests Stirling freezer business for $1; cuts 11% of workforce
Sold Global Cooling (Stirling) for $1.00; expects to eliminate several million dollars of quarterly cash burn.
BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive
Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.
Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders
Max materiality 0.80 · Median 0.70 · Most common event earnings